Sponsored by:
MICROSPHERES AND NANOPARTICLES FOR PEPTIDE DELIVERY
Delivery of peptides is a challenging task due to their poor stability toward proteolytic enzymes, their large size and poor penetration into cells
Delivery of peptides is a challenging task due to their poor stability toward proteolytic enzymes, their large size and poor penetration into cells. The great innovation in this field relies on the formulation of microspheres and nanoparticles to encapsulate the peptide in order to enhance its bioavailability and therapeutic efficacy.
Microparticle formulation has been successfully applied in a number of commercial products containing peptides as active pharmaceutical ingredients. The use of nanoparticles for delivering proteins and peptides are still in early stages of development and is expected to mature in near future.
To discover more on how Bachem is part of this technology in achieving successful formulation of APIs, please read our white paper on the benefits and challenges of microspheres and nanoparticles for peptide delivery.
About Bachem:
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
